Taiwan biotech and contract manufacturing organization (CMO) EirGenix has opened a protein production facility in Hsinchu, Taiwan.
With a maximum capacity of six 2000L single use bioreactors, the facility is scheduled to test mass production in March.
The facility is for EirGenix’ CMO business as well as the biosimilars developed on its own.
For example, its trastuzumab biosimilar EG12014 is expected to complete the global Phase III studies by 2020.
In October last year, EG12014 was approved for Phase III clinical trial by the US Food and Drug Administration, Taiwan FDA, and regulatory authorities from Georgia, Russia, Belarus, South Korea, India, Chile and Ukraine, and first patient has enrolled.
The company will also support its Spanish client Oncomatryx to develop an ADC to treat pancreatic cancer.
Source: The Pharma Letter
Catherine Hung (email@example.com)
l Taiwantrade news center: https://www.taiwantrade.com/mp/news-center